The new drug Enveroquzu Monoclonal Antibody Injection developed by the Stone Pharmaceutical Group (01093.HK) has been accepted by the National Medical Products Administration for market approval.

The Smart Finance and Economics APP news, Sinopharm Group (01093.HK) announced that the new drug Enlibrutuzumab Injection developed by the group has been accepted for market application by the National Medical Products Administration of the People's Republic of China. The product is declared as a Class 1 new drug for therapeutic biologics, indicated for unresectable or metastatic HER2-positive adult breast cancer patients who have previously received one or more anti-HER2 drugs.